Investors Rally Behind IBRX Class Action Amid FDA Violations, Seeking Lead Plaintiff Role

IBRX Class Action Lawsuit: Investors Unite Against Alleged Fraud

In a significant development for investors of ImmunityBio, Inc. (NASDAQ: IBRX), a class action lawsuit has been filed that prompts shareholders to consider leading the charge against the company, alleging serious violations of FDA drug regulations. This comes after the FDA declared certain promotional communications by ImmunityBio to be false or misleading, resulting in a sharp decline of 21% in share value.

Important Dates and Context

The crucial date for investors looking to serve as lead plaintiffs is May 26, 2026. This class action, spearheaded by the law firm Levi & Korsinsky, LLP, seeks to hold ImmunityBio accountable for its misleading practices that have reportedly harmed numerous investors between January 19, 2026, and March 24, 2026. During this period, ImmunityBio shares fell significantly, which affected many stakeholders financially.

What Does it Mean to Be a Lead Plaintiff?

Under the Private Securities Litigation Reform Act of 1995 (PSLRA), an investor can apply to be appointed as the lead plaintiff if they have endured losses due to the alleged fraudulent misbehavior of a company. This role is crucial as the lead plaintiff oversees the litigation strategy and selects the law firm representing the entire class of investors.

Joseph E. Levi, Esq. emphasizes, “The lead plaintiff process ensures that the class is appropriately represented by shareholders with substantial financial interests in the case.” This means that even without being the lead plaintiff, investors can still potentially recover losses from any settlement achieved.

How to Get Involved

If you are an investor who purchased IBRX securities during the aforementioned class period and experienced losses, you may be eligible to seek lead plaintiff status. However, there’s no minimum threshold for financial loss; anyone who suffered a loss can apply.

The process entails filing a motion by the deadline, after which the court will review all submissions and select the most suitable lead plaintiff within 30 to 60 days. It’s important to gather all relevant purchase records, including transaction dates and share quantities. The law firm offers a free evaluation of your eligibility for group or individual claims.

Absent Class Members' Rights

Investors who do not apply for lead plaintiff status still maintain their rights as absent class members. They have the option to object to any proposed settlements and can submit claims to recover their proportional shares of any future settlements achieved through the lawsuit.

What’s Next for IBRX Investors?

Gathering brokerage records is the first step for concerned shareholders. For those who may be interested in filing for lead plaintiff status or simply want to know their options moving forward, reaching out to Levi & Korsinsky is advisable. The firm is well-regarded in the securities field and provides essential guidance for investors looking to navigate the complexities of class action lawsuits.

Contact Information

For additional inquiries or to begin your claim, contact Joseph E. Levi, Esq. at Levi & Korsinsky by calling (212) 363-7500 or emailing [email protected].

In the wake of this litigation, ImmunityBio shareholders must act promptly to protect their interests and ensure they have a voice in the unfolding legal proceedings. Time is of the essence, and the May 26 deadline is approaching fast, compelling many investors to take necessary actions to safeguard their investments.